| Identification | Back Directory | [Name]
ALK-IN-27 | [CAS]
2739866-40-9 | [Synonyms]
ALK-IN-27
(R)-1-chloro-3-ethyl-12-fluoro-10,16-dimethyl-3,10,16,18-tetrahydro-4,8-(metheno)benzo[l]dipyrazolo[3,4-g:4',3'-j][1]oxa[4]azacyclotetradecin-7-amine | [Molecular Formula]
C23H22ClFN6O | [MOL File]
2739866-40-9.mol | [Molecular Weight]
452.91 |
| Chemical Properties | Back Directory | [Boiling point ]
685.0±55.0 °C(Predicted) | [density ]
1.46±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted) | [form ]
Solid | [pka]
7.11±0.40(Predicted) | [color ]
White to off-white | [InChIKey]
FWZSCAQEBTVTOM-GFCCVEGCSA-N | [SMILES]
C(N1N=C(C2CC3=CN(N=C3C3=CC=C(C=C3[C@H](OC3=C(N=CC(=C3)C=21)N)C)F)C)Cl)C |
| Hazard Information | Back Directory | [Uses]
Neladalkib (NVL-655) is an oral ALK inhibitor, the IC50 for Neladalkib in inhibiting ALK is 2.8 nM. Neladalkib promotes cell apoptosis and has anti-tumor activity[1][2]. | [in vivo]
Neladalkib (0.06-1.5 mg/kg, orally, twice daily, days 0-28) has antitumor activity in mice[2]. | Animal Model: | ALK-driven tumor xenografts in mice[2] | | Dosage: | 0.06, 0.2, 0.5, 1.5 mg/kg | | Administration: | Oral | | Result: | Inhibited tumor proliferation. |
| [References]
[1] Jennifer Anne Green, et al. Methods of treating solid tumor using (19r)-5-chloro-3-ethyl-16-fluoro-10,19-dimethyl-20-oxa-3,4,10,11,23-pentaazapentacyclo[19.3.1.02,6.08,12.013,18]pentacosa-1(24),2(6),4,8,11,13,15,17,21(25),22-decaen-22-amine. WO2023196910A1.
[2] Jessica J Lin, et al. NVL-655 Is a Selective and Brain-Penetrant Inhibitor of Diverse ALK-Mutant Oncoproteins, Including Lorlatinib-Resistant Compound Mutations. Cancer Discov. 2024 Sep 13:OF1-OF20. DOI:10.1158/2159-8290.CD-24-0231 |
|
| Company Name: |
Jia Xing Isenchem Co.,Ltd
|
| Tel: |
0573-85285100 18627885956 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList14265/0_EN.htm |
|